Last reviewed · How we verify
Single antiplatelet therapy
Single antiplatelet therapy is a Antiplatelet agent Small molecule drug developed by China National Center for Cardiovascular Diseases. It is currently FDA-approved for Cardiovascular disease prevention, Acute coronary syndrome, Stroke prevention.
Single antiplatelet therapy inhibits platelet aggregation to reduce thrombotic events in cardiovascular disease.
Single antiplatelet therapy typically involves the use of a single medication, such as aspirin, to prevent blood clots. This treatment is studied in various conditions, including coronary artery disease, acute ischemic stroke, and intracranial arteriosclerosis, according to ClinicalTrials.gov.
At a glance
| Generic name | Single antiplatelet therapy |
|---|---|
| Sponsor | China National Center for Cardiovascular Diseases |
| Drug class | Antiplatelet agent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Antiplatelet agents work by interfering with platelet activation and clumping through various mechanisms such as cyclooxygenase inhibition, ADP receptor antagonism, or phosphodiesterase inhibition. This prevents thrombus formation and reduces the risk of myocardial infarction, stroke, and other ischemic cardiovascular events. Single antiplatelet therapy typically refers to monotherapy with agents like aspirin or P2Y12 inhibitors.
Approved indications
- Cardiovascular disease prevention
- Acute coronary syndrome
- Stroke prevention
Common side effects
- Bleeding
- Gastrointestinal upset
- Dyspepsia
Key clinical trials
- A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (PHASE3)
- Medical Treatment With or Without Transcatheter Patent Foramen Ovale Closure (NA)
- OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation (PHASE4)
- A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease (PHASE1, PHASE2)
- Comparing Two PFO Closure Devices in Adults With Previous Stroke or TIA (NA)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation (NA)
- Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Single antiplatelet therapy CI brief — competitive landscape report
- Single antiplatelet therapy updates RSS · CI watch RSS
- China National Center for Cardiovascular Diseases portfolio CI
Frequently asked questions about Single antiplatelet therapy
What is Single antiplatelet therapy?
How does Single antiplatelet therapy work?
What is Single antiplatelet therapy used for?
Who makes Single antiplatelet therapy?
What drug class is Single antiplatelet therapy in?
What development phase is Single antiplatelet therapy in?
What are the side effects of Single antiplatelet therapy?
Related
- Drug class: All Antiplatelet agent drugs
- Manufacturer: China National Center for Cardiovascular Diseases — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Cardiovascular disease prevention
- Indication: Drugs for Acute coronary syndrome
- Indication: Drugs for Stroke prevention
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing